

2026 BIOMARKERS CONFERENCE AGENDA

**PROCEEDING TOWARDS THE ESTABLISHMENT OF A NATIONAL STRATEGY FOR ADVANCING CGP IN METASTATIC CANCER CARE:
ALIGNING PATIENT, CLINICAL, AND POLICY PERSPECTIVES**

TARGET AUDIENCE: Oncology Professionals, Pathologists, Patients and Caregivers, Advocates, Researchers, Policy Professionals, Industry

Goals: Education, Awareness, Advocacy

**Steering Committee: Dr. Monika Krzyzanowska (Co-Chair), Dr. Shantanu Banerji (Co-Chair),
Dr. Mita Manna, Dr. Doha Itani, Don Husereau, Matthew Brougham, Dr. Georgia Balsevich, Katie Hulan**

DAY 1: JUNE 18, 2026

LAYING THE FOUNDATION FOR THE ESTABLISHMENT OF A NATIONAL STRATEGY FOR CGP READINESS

Time	Session Title & Descriptions	Presenters/Speakers
9:30 a.m. – 9:45 a.m.	<p>Conference Day 1 Opening</p> <p>The Conference will begin with opening remarks, an overview of the program, and a look at the key themes that will guide discussions over the next two days.</p> <p>CCRAN is a national, patient-focused advocacy organization dedicated to improving the longevity and quality of life of people affected by cancer through support, education, and advocacy for equitable and timely access to effective therapies.</p> <p>Now in its fourth year, the Pan-Tumour Biomarkers Conference convenes clinicians, pathologists, researchers, policy professionals, patients, and caregivers from Canada and internationally. Building on the momentum of previous conferences, this year's program is centered on the establishment of a national strategy for advancing comprehensive genomic profiling (CGP) in metastatic cancer care.</p>	<p><i>Conference Moderator:</i> Cassandra Macaulay, B.Sc., MHS, RTNM Chief Research Officer, CCRAN</p>

	Discussions will explore opportunities to better align patient, clinical, and policy perspectives in support of a more coordinated and sustainable approach to CGP implementation across Canada.	
9:45 a.m. – 10:00 a.m.	<p>Welcome from CCRAN’s President & CEO</p> <p>A welcome from CCRAN's President & CEO, followed by a conversation with a patient advocate reflecting on their cancer journey. Through the lens of lived experience, the discussion will explore the realities of navigating cancer and the insights patients can offer in advancing more responsive, equitable, and person-centred care.</p>	<p>Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A. President & CEO, CCRAN</p> <p><i>Patient Perspective</i> Eric Hamilton Stage IV Colorectal Cancer Patient; Patient Advocate</p>
10:00 a.m. – 10:30 a.m.	<p>Key Learnings from CCRAN’s 2025 Biomarkers Conference</p> <p>The objectives and outcomes of CCRAN’s 2025 Biomarkers Conference have been captured and summarized in a publication in Current Oncology.</p> <p>The lead author of the publication will present the key findings, themes and calls to action as highlighted in the paper.</p>	<p><i>Presentation</i> Dr. Stephanie Snow, MD, FRCPC Medical Oncologist, QEII Health Sciences Centre; Professor, Dalhousie University</p>
10:30 a.m. – 11:45 a.m.	<p>Economic and Health System Readiness: Leveraging Evidence to Support Comprehensive Genomic Profiling Integration Across Canada</p> <p>To build a sustainable and equitable precision oncology framework, stakeholders require both a compelling economic case and a clear understanding of health system readiness for routine genome-based testing. This presentation draws on two complementary bodies of work, the comprehensive genomic profiling (CGP) cost and benefit analysis findings and the State of Readiness Progress Report II, which examines the conditions required to support the routine use of genomic testing across Canada. Together, these perspectives will highlight jurisdictional progress, persistent system gaps, and the role of real-world evidence to inform coordinated decision-making. The session will support a national conversation on how economic evidence and readiness assessment can guide CGP planning and alignment across provinces and sectors.</p> <p>This presentation will focus on:</p> <ul style="list-style-type: none"> Assessing current system readiness for routine genomic testing, including progress and persistent challenges across jurisdictions 	<p><i>Keynote Presentation</i> Don Husereau, B.Sc. Pharm, M.Sc. Adjunct Professor of Medicine, University of Ottawa</p> <p>Eddy Nason, MPhil, B.Sc. Director, Health, Signal49 Research</p>

	<ul style="list-style-type: none"> • Examining economic evidence for CGP and what it means for real-world funding and system decision-making • Identifying practical opportunities to advance coordinated, pan-Canadian CGP implementation 	
11:45 a.m. – 12:30 p.m.	<p>Health Break</p> <p>Virtual Networking Room Hosted by Merck (11:45 a.m. - 12:15 p.m.)</p> <p><i>Moderated by: Don Wood, Community & Patient Engagement Specialist, CCRAN</i> <i>Merck Leads: Constance Planchet, Diagnostic Commercial Lead, Precision Medicine, Oncology, Merck</i> Jeff Guiler, Director, Strategic Collaborations & New Assets, Oncology, Merck</p>	
12:30 p.m. – 1:00 p.m.	<p>CDA’s Framework for Equitable Biomarker Testing Access: Key Recommendations and Future Directions</p> <p>Canada's Drug Agency (CDA) report, <i>Assessment Framework for Cancer Biomarkers: A Report From the Biomarker Advisory Panel</i>, represents a critical step toward improving equitable access to biomarker testing across Canada. This presentation will introduce the purpose and structure of the Framework, highlighting its potential to support more consistent, evidence-informed decision-making and system-wide coordination. Attendees will hear from CDA about the Framework’s objectives, including short- and medium-term strategies to support implementation and collaboration across jurisdictions. The discussion will also highlight opportunities for shared infrastructure, coordinated data access, and policy levers to support adoption.</p> <p>Session objectives:</p> <ul style="list-style-type: none"> • Introduce the Assessment Framework for Cancer Biomarkers and its role in supporting equitable biomarker testing decision-making across Canada • Outline implementation timelines, early priorities, and mechanisms for interprovincial collaboration • Highlight opportunities for alignment and collaboration across provinces and sectors to enable shared infrastructure, data access, and assessment processes 	<p><u>Presentation</u></p> <p>Dr. Laura Weeks, Ph.D. Director, Health Technology Assessment, Canada’s Drug Agency</p>

<p>1:00 p.m. – 2:00 p.m.</p>	<p>Stakeholder Reflections on CDA’s Assessment Framework for Cancer Biomarkers: A Cross-Sector Dialogue</p> <p>Following the presentation of the Assessment Framework for Cancer Biomarkers, this multi-stakeholder panel will examine its practical implications and translational potential across jurisdictions. Panelists from clinical, regulatory, policy, and patient advocacy sectors will share diverse perspectives on the Framework’s relevance, anticipated challenges, and opportunities for cross-sector alignment. The discussion will explore how a truly national approach to biomarker testing can be equitably implemented and sustainably scaled, with a focus on shared infrastructure, governance mechanisms, and meaningful integration of patient voice.</p> <p>Key objectives to be explored:</p> <ul style="list-style-type: none"> • Reflect on the Assessment Framework for Cancer Biomarkers through clinical, policy, regulatory, and patient lenses • Explore opportunities to strengthen national alignment and equitable access to biomarker testing across Canada • Discuss what is needed to support transparent and coordinated implementation of the Framework as Canada advances biomarker testing across jurisdictions 	<p><i>Moderator</i> Bill Dempster President, 3Sixty Public Affairs</p> <p><i>Patient Perspective</i> Dr. Catalina Lopez-Correa, MD, Ph.D. Breast Cancer Survivor and Advocate; Vice-Chair, Global Genomics Network for Education and Training (GGNET); Co-Chair, Patient Working Group, Marathon of Hope Cancer Centres Network</p> <p><i>Panelists</i> Cassandra Macaulay, B.Sc., MHS, RTNM Chief Research Officer, CCRAN</p> <p>Dr. Laura Weeks, Ph.D. Director, Health Technology Assessment, Canada’s Drug Agency</p> <p>Dr. Sharlene Gill, MD, MPH, MBA, FASCO Professor of Medicine, UBC; Medical Oncologist, BC Cancer - Vancouver; Medical & Scientific Advisory Board Co-Chair, Colorectal Cancer Resource & Action Network (CCRAN)</p> <p>Laura Greer Patient Expert; Executive Vice President and Global Client Lead, Health & Wellness, Burson Canada; Breast Cancer Advocate</p>
------------------------------	---	--

<p>2:00 p.m. – 3:00 p.m.</p>	<p>The Patient Voice Amplified: CGP Making a Difference in the Canadian Cancer Care Landscape Across Tumour Types</p> <p>As Canada considers implementation of comprehensive genomic profiling (CGP) in metastatic cancer care, lived experience offers critical insight into how testing is accessed, understood, and integrated into care. This session brings forward the voices of patients across tumour types reflecting a range of experiences with genomic testing.</p> <p>Panelists will share how testing has influenced treatment decisions and care experiences, while also highlighting challenges related to referral pathways, timing, and clarity around what testing was performed and how results were used. These insights reflect the current variability across jurisdictions and care settings. As system-level planning advances, these perspectives underscore the importance of consistent access to CGP, clearer integration into care pathways, and improved communication across the diagnostic and treatment continuum.</p> <p>Discussion objectives:</p> <ul style="list-style-type: none"> • Explore how genomic testing has influenced care experiences, treatment decisions, and access to personalized treatment options • Identify gaps in access to testing, including challenges related to geography, availability, timing, and integration into care • Demonstrate how lived experience can inform health system planning, clinical practice, and policy development 	<p><i>Moderator</i> Eva Villalba, MBA, M.Sc. VBHC Green Belt; Executive Director, Quebec Cancer Coalition; President, VBHC Learning Community</p> <p><i>Patient Panel</i> Corri Desaulniers Stage IV Cholangiocarcinoma Patient, FGFR2 Fusion; Patient Partner & Advocate, Canadian Cholangiocarcinoma Collaborative (C3)</p> <p>Mariana Markovic, RN, MN, MHSC, CHE Stage IV Colon Cancer Survivor; Healthcare Consultant, Independent Healthcare Consulting Inc.; Patient Advocate</p> <p>Laura Greer State IV Breast Cancer Survivor & Advocate; Patient Expert; Executive Vice President and Global Client Lead, Health & Wellness, Burson Canada</p> <p>Dr. Mary K. Bryson, Ph.D. Stage IV EGFR Lung Cancer Patient; International Association for the Study of Lung Cancer (IASLC) STARS Scholar Patient Advocate; Professor, Department of Language and Literacy Education (LLED), Faculty of Education, The University of British Columbia</p> <p>Brad Sluiter Stage IV Pancreatic Cancer Patient</p>
<p>3:00 p.m. – 3:15 p.m.</p>	<p style="text-align: center;">Health Break</p> <p style="text-align: center;">Featured Video: Second Look Cancer - Clinical Trial Matching Tool</p> <p style="text-align: center;">Dillan Eisenhaur, Founder</p>	

<p>3:15 p.m. – 4:45 p.m.</p>	<p>Molecular Tumour Boards in Practice: Advancing Standardization and System Readiness</p> <p>Molecular Tumour Boards (MTBs) play a pivotal role in translating complex genomic and molecular testing results into clinical decision-making. As the use of comprehensive genomic profiling (CGP) and other advanced testing approaches continues to expand across Canada, MTBs are increasingly central to ensuring consistent interpretation and equitable access to precision oncology expertise. Yet MTB structure, availability, and functionality vary widely across jurisdictions. This session will examine how MTBs contribute to standardizing interpretation of CGP results, while exploring emerging models that support integration of MTBs into routine care.</p> <p>As molecular testing becomes more complex, the discussion will also consider the importance of clinician education and ongoing knowledge support in strengthening genomics literacy and enabling effective interpretation of increasingly detailed molecular reports, particularly in settings where formal MTB infrastructure may be limited.</p> <p>Key objectives:</p> <ul style="list-style-type: none"> • Examine the role of MTBs in interpreting CGP and other advanced genomic testing results to support informed clinical decision-making • Explore current MTB models across Canada, including variations in implementation and opportunities to strengthen integration into care • Identify strategies to strengthen clinician education and knowledge-sharing in support of genomic-informed care 	<p><u>Moderator</u> Dr. Michael Raphael, MD, FRCPC Medical Oncologist, Early Age Onset CRC Cancer Clinic Lead, Odette Cancer Centre, Sunnybrook Health Sciences Centre; Co-Chair, Medical & Scientific Advisory Board, CCRAN</p> <p><u>Caregiver Perspective</u> Jennifer Willis Caregiver to spouse diagnosed with Stage IIIC Cholangiocarcinoma</p> <p><u>Panelists</u> Dr. Alan Spatz, MD, M.Sc. Professor, Departments of Pathology & Oncology, McGill University; Chief, Department of Clinical Laboratory Medicine, MUHC; Medical Director, Optilab Montreal-MUHC Network</p> <p>Prof. Arndt Vogel, MD, Ph.D. Clinician Scientist, Division of Gastroenterology and Hepatology, Toronto General Hospital & Medical Oncology, Princess Margaret Cancer Centre; Professor of Medicine, University of Toronto</p> <p>Dr. Erin DeBruin Manager, Professional Education and Implementation, Genome BC</p> <p>Dr. Shantanu Banerji, B.Sc. (Med), MD, FRCPC Co-Chair, Expert Steering Committee; Director of Precision Oncology and Advanced Therapeutics, CancerCare Manitoba</p>
------------------------------	--	--

<p>4:45 p.m. – 5:45 p.m.</p>	<p>Driving Access Through Partnership: The Role of Industry in Canada’s Precision Oncology Landscape</p> <p>As Canada advances toward more coordinated and equitable access to comprehensive genomic profiling (CGP), industry partners play an important role in helping address longstanding barriers related to infrastructure, education, turnaround times, and system capacity. This session will explore how thoughtful and transparent collaboration across public and private stakeholders can help strengthen CGP readiness across provinces while supporting a patient-centred and evidence-informed approach to precision oncology.</p> <p>Through a national panel discussion, experts will examine opportunities to align industry innovation with oncology system priorities, enhance cross-sector coordination, and contribute to sustainable models that support equitable access to CGP across Canada. The discussion will also explore how industry and health system partners can collaborate to navigate operational realities and foster sustainable partnerships that advance CGP across jurisdictions.</p> <p>This session will explore:</p> <ul style="list-style-type: none"> • How industry partners can support the advancement of CGP within Canada’s evolving precision oncology landscape • Opportunities for collaboration across industry, policy, clinical, and patient communities to support coordinated approaches to CGP • Considerations for fostering responsible and sustainable partnerships that align innovation with health system priorities and patient needs 	<p><i>Moderator</i> Dr. Georgia Balsevich, Ph.D. Senior Sector Innovation Manager, Genome Alberta</p> <p><i>Caregiver Perspective</i> Don Wood Caregiver to spouse who succumbed to Stage IV Colorectal Cancer; Community & Patient Engagement Specialist, CCRAN</p> <p><i>Panelists</i> Dr. André Galarneau, M.Sc., Ph.D. Executive Director & Vice-President, Oncology Business Unit, Merck Canada Inc.</p> <p>Dr. Paul Krzyzanowski, Ph.D., MBA Medical Affairs Director, Precision Medicine, Johnson & Johnson</p> <p>Mark Oatway Head, Diagnostics and Transforming Care, Oncology, AstraZeneca Canada</p> <p>Hon. John Wilkinson Former Ontario Minister of Research & Innovation</p> <p>Dr. Michael Mengel, MD Professor, Department of Laboratory Medicine & Pathology, University of Alberta; Director, Alberta Transplant Institute; North Sector Medical Director, Alberta Precision Laboratories (APL)</p>
<p>5:45 p.m. – 5:50 p.m.</p>	<p>Glance at Day 2. Closing Remarks from CCRAN’s President & CEO.</p>	<p>Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A. President & CEO, CCRAN</p>

2026 BIOMARKERS CONFERENCE AGENDA

**PROCEEDING TOWARDS THE ESTABLISHMENT OF A NATIONAL STRATEGY FOR ADVANCING CGP IN METASTATIC CANCER CARE:
ALIGNING PATIENT, CLINICAL, AND POLICY PERSPECTIVES**

DAY 2: JUNE 19, 2026

ADVANCING THE VISION: LEVERAGING CLINICAL EVIDENCE AND THE PATIENT VOICE

Time	Session Title & Descriptions	Expert Speakers
9:30 a.m. – 9:45 a.m.	<p>Conference Day 2 Opening</p> <p>A brief recap of key themes, insights, and discussions from Day 1, followed by an overview of the objectives and discussions that will shape Day 2 of the Conference.</p>	<p><i>Conference Moderator:</i> Cassandra Macaulay, B.Sc., MHS, RTNM Chief Research Officer, CCRAN</p>
9:45 a.m. – 10:00 a.m.	<p>Welcome to Day 2 from CCRAN’s President & CEO</p> <p>A welcome to Day 2 from CCRAN's President & CEO, followed by a conversation with a patient advocate reflecting on their cancer journey. Through the lens of lived experience, the discussion will explore the realities of navigating cancer and the insights patients can offer in advancing more responsive, equitable, and person-centred care.</p>	<p>Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A. President & CEO, CCRAN</p> <p><i>Patient Perspective</i> Michelle Audoin Chair, Patient Representative Committee, Canadian Cancer Trials Group (CCTG); Patient Advocate and Community Collaborator; All.Can Canada Evidence Working Group; Stage IV Breast Cancer and Thyroid Cancer Patient</p>

<p>10:00 a.m. – 11:30 a.m.</p>	<p>A National Conversation on CGP Becoming a Standard of Care</p> <p>As provinces across Canada work to advance access to comprehensive genomic profiling (CGP), clinical teams are navigating varying system conditions, infrastructure, and expectations. This national roundtable will bring together frontline clinicians to build clinical consensus that CGP <i>should</i> be established as a standard of care, and to identify the conditions needed to support equitable, informed clinical decision-making across Canada.</p> <p>Panelists will reflect on their jurisdictional contexts, identifying shared challenges and enablers related to team capacity, informatics, turnaround times, and lab resources. Rather than prescribing a uniform approach, the session will focus on identifying where alignment is most needed, across care settings, provinces, and specialties, to advance CGP in a way that is both scalable and responsive to local needs.</p> <p>Key objectives:</p> <ul style="list-style-type: none"> • Examine the clinical value of CGP relative to current testing approaches and its role in supporting more informed treatment decision-making • Identify the key conditions required to support the integration of CGP into clinical care • Explore opportunities to strengthen consistency in the use of CGP in clinical practice across care settings and jurisdictions 	<p><u>Moderator</u> Dr. Monika Krzyzanowska, MD, MPH, FRCPC, FASCO Co-Chair, Expert Steering Committee; Chief & Medical Oncologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre; Regional Vice President, Ontario Health (Cancer Care Ontario); Professor of Medicine, University of Toronto</p> <p><u>Caregiver Perspective</u> Neil Marr, Hon B.A. Caregiver to spouse who succumbed to Stage IV Cholangiocarcinoma; Research Advocate and Mentor; Patient Partner with PanCuRx</p> <p><u>Clinician Roundtable</u> Dr. Mita Manna, MD, FRCPC Medical Oncologist, Saskatoon Cancer Centre; Associate Professor, Department of Oncology, University of Saskatchewan</p> <p>Dr. Stephanie Snow, MD, FRCPC Medical Oncologist, QEII Health Sciences Centre; Professor, Dalhousie University</p> <p>Dr. Rebecca Auer, MD, M.Sc., FRCSC, FACS Executive Vice-President, Research & Innovation, The Ottawa Hospital; CEO & Scientific Director, Ottawa Hospital Research Institute; Professor, Departments of Surgery, Biochemistry, Immunology & Microbiology, University of Ottawa</p> <p>Dr. Shantanu Banerji, B.Sc. (Med), MD, FRCPC Co-Chair, Expert Steering Committee; Director of Precision Oncology and Advanced Therapeutics, CancerCare Manitoba</p>
--------------------------------	---	---

		<p>Dr. Yoo-Joung Ko, MD, MMS, M.Sc. Medical Oncologist, St. Michael's Hospital, Unity Health; Medical Director, Cancer & Endoscopy Program, Unity Health</p> <p>Dr. Urban Emmenegger, MD Medical Oncologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre; Associate Professor, Department of Medicine, University of Toronto</p> <p>Dr. Jason Karamchandani, MD Associate Professor, Departments of Pathology, Neurology and Neurosurgery, McGill University; President, Canadian Association of Pathologists</p>
11:30 a.m. – 12:15 p.m.	<p>Health Break</p> <p>Educational Videos</p>	
12:15 p.m. – 1:30 p.m.	<p>Unlocking the Research Pipeline: Bridging Clinical Trials and Real-World Genomics</p> <p>As comprehensive genomic profiling (CGP) moves toward standard of care, attention is shifting from generating genomic data to understanding how that information can be used to improve decision-making across the cancer system. This session examines how clinical trials, real-world genomic data, and coordinated research infrastructure can strengthen Canada's precision oncology ecosystem, particularly where traditional evidence pathways are limited.</p> <p>By examining how genomic data is generated, shared, and applied across the cancer system, the discussion will explore how genomics can strengthen research, inform policy and system decision-making, and advance a more coordinated pan-Canadian approach to precision oncology.</p> <p>This session will explore:</p> <ul style="list-style-type: none"> • Gaps in clinical trial inclusion for metastatic cancer patients eligible for CGP, and their impact on access 	<p><u>Moderator</u> Dr. Stéphanie Michaud, Ph.D. President and CEO, BioCanRx</p> <p><u>Patient Perspective</u> Dillan Eisenhour Stage IV Colorectal Cancer Patient; Founder, Second Look Cancer Inc.</p> <p><u>Panelists</u> Dr. Yvonne Bombard, Ph.D. Canada Research Chair, Genomics Health Services & Policy, Unity Health Toronto; Professor, University of Toronto; Director, Genomics Health Services Research Program, St. Michael's Hospital; Co-Founder & CEO, Genetics Adviser</p>

	<ul style="list-style-type: none"> • The role of real-world genomic data in informing patient-centred policy and system decision-making • How national genomic repositories and data-sharing platforms can support a coordinated, pan-Canadian research and innovation strategy • Collaborative research models that integrate CGP into clinical and translational studies 	<p>Dr. Jim Woodgett President and Scientific Director, The Terry Fox Research Institute (TFRI)</p> <p>Dr. Arvind N. Dasari, MD Director of Clinical Research, Dept. of GI Medical Oncology, University of Texas MD Anderson Cancer Center, USA</p>
<p>1:30 p.m. – 3:00 p.m.</p>	<p>Patient Group Reflections on the Case for CGP Investment</p> <p>As health systems across Canada consider the integration of CGP into standard cancer care, patient groups play a critical role in highlighting access gaps and articulating priorities for investment. This roundtable brings together patient organizations from across tumour types to reflect on their experiences advocating for CGP within diverse health system contexts. The discussion will explore how patient groups identify unmet needs, coordinate advocacy efforts, and define what meaningful CGP investment looks like from a patient and community perspective.</p> <p>The discussion will also include early reflections on CCRAN’s CGP Phase II Research Initiative, focusing on how real-world evidence can help inform future decision-making and support more consistent implementation of CGP across Canada.</p> <p>Speakers will elaborate on the following topics:</p> <ul style="list-style-type: none"> • The role of real-world evidence in informing CGP implementation • How patient groups are engaging stakeholders to shape priorities and inform decision-making to advance CGP as a standard of care across Canada • Barriers to achieving consistent access and standardization of CGP testing across jurisdictions • Strategic approaches to strengthen advocacy impact across jurisdictions 	<p><i>Moderator</i></p> <p>Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A. President & CEO, CCRAN</p> <p><i>Patient Group Roundtable</i></p> <p>Ayelet Borgida, M.Sc. Director of Medical and Health Initiatives, Pancreatic Cancer North America</p> <p>Lindsay Timm Executive Director, Canadian Cancer Survivor Network (CCSN)</p> <p>Winky Yau Manager, Medical Affairs, Lung Cancer Canada</p> <p>Teresa Norris Sexual Health Specialist; Founder & President, HPV Global Action</p> <p>JK Miller Health Policy & Advocacy Lead, Canadian Breast Cancer Network</p> <p>Laz Bouros President, Thyroid Foundation of Canada</p>

		<p>Austin Zimmer, B.Sc., M.Sc. Support Services Manager & Research Coordinator, Prostate Cancer Foundation Canada</p> <p>Shannon Phillips BSW Locally Advanced Triple-Negative Breast Cancer & Gastric Cancer Survivor; Board Member, My Gut Feeling – Stomach Cancer Foundation of Canada</p>
3:00 p.m. – 3:15 p.m.	<p>Health Break</p> <p>Featured Video: Cancer Is Personal. Care Should Be Too. <i>A collective reflection from our patient group partners</i></p>	
3:15 p.m. – 4:15 p.m.	<p>Scaling What Matters: Building on Economic Evidence to Help Inform Policy</p> <p>As Canada progresses toward a more aligned approach to comprehensive genomic profiling (CGP) in metastatic cancer care, economic evidence is emerging as a central lever for advancing shared understanding across clinical, policy, and patient communities. Drawing on findings from Precision in Practice, CCRAN's national cost and benefit analysis developed in partnership with Signal49 Research, this session will explore how economic evidence can clarify the value of CGP from multiple vantage points and support a more coordinated national dialogue.</p> <p>Panelists will reflect on how economic insights can be translated into strategic, scalable approaches to inform future system planning. The discussion will emphasize where stakeholder priorities converge and how economic considerations can be used to inform coordinated CGP planning across Canada.</p> <p>Guiding objectives include:</p> <ul style="list-style-type: none"> • Examining key findings from the CGP cost and benefit analysis and their implications for future decision-making • Engage diverse stakeholder perspectives on what is needed to move from emerging evidence to a more coordinated national approach to CGP implementation • Demonstrating how collaborative models can strengthen system readiness for the implementation of CGP across clinical, policy, and operational domains 	<p><i>Moderator</i> Dr. Étienne Richer, Ph.D. Director of Genomics Programs, Genome Canada</p> <p><i>Patient Perspective</i> Steve Slack Stage IV Colon Cancer Survivor</p> <p><i>Panelists</i> Eddy Nason, MPhil, B.Sc. Director, Health, Signal49 Research</p> <p>Matthew Brougham Senior Global Consultant, Certara Evidence & Access; President & CEO, Brougham Consulting Inc.</p> <p>Dr. Steven Narod, MD Senior Scientist, Women's College Hospital Research Institute; Professor, Dalla Lana School of Public Health and Department of Medicine, University in Toronto</p> <p>Dr. Sandeep Sehdev, MD, FRCPC Medical Oncologist, The Ottawa Hospital Cancer Centre; Associate Professor of Medicine, University of Ottawa</p>

<p>4:15 p.m. – 5:15 p.m.</p>	<p>From Laboratory Readiness to Patient Impact: Why CGP Falls Short and What Must Change</p> <p>Comprehensive genomic profiling (CGP) is increasingly recognized as an integral component of precision oncology and metastatic cancer care. However, despite growing clinical and economic evidence supporting its value, access remains fragmented across Canada.</p> <p>While many centres have developed strong genomic capabilities, implementation remains variable across jurisdictions. This session examines the most pressing constraints preventing CGP becoming routine practice, with a particular focus on laboratory capacity, diagnostic workflows, and system readiness conditions.</p> <p>The discussion connects system-level barriers, such as variable testing criteria, turnaround times, and disconnected diagnostic pathways, to their impact on patient care. The session will examine how these system constraints affect the timing and quality of treatment decision-making within cancer care. By examining system and policy considerations through a real-world patient lens, the session aims to clarify where breakdowns occur and what is required to move CGP and advanced genomic testing from fragmented access to sustained, reliable integration within routine cancer care.</p> <p>This multi-disciplinary panel will explore:</p> <ul style="list-style-type: none"> • Key laboratory, diagnostic, and system-level barriers limiting the consistent implementation of CGP and other advanced genomic testing across Canada • Health system and workforce considerations, including laboratory capacity, health human resources, and interprofessional collaboration required to support scalable genomic testing • Practical readiness conditions and system enablers needed to support the routine, accountable integration of CGP into cancer care 	<p><u>Moderator</u> Andrea Tjahja, MLT, ART, B.Sc., B.Ed. Vice President, Operations, Medical Laboratory Professionals' Association of Ontario (MLPAO)</p> <p><u>Patient Perspectives</u> Dr. Christine Qiong Wu, M.Sc., Ph.D. Stage IV Lung Cancer Patient; Professor of Engineering, University of Manitoba</p> <p>Michelle Audoin Chair, Patient Representative Committee, Canadian Cancer Trials Group (CCTG); Patient Advocate and Community Collaborator; All.Can Canada Evidence Working Group; Stage IV Breast Cancer and Thyroid Cancer Patient</p> <p><u>Panelists</u> Craig Ivany, B. Comm, MBA, CHE, ICD.D Adjunct Professor, Pathology and Laboratory Medicine, University of British Columbia</p> <p>Andrea Beharry Manager, Clinical Services, Advanced Diagnostics, William Osler Health System</p> <p>Dr. Jason Karamchandani, MD Associate Professor, Departments of Pathology, Neurology and Neurosurgery, McGill University; President, Canadian Association of Pathologists</p> <p>Prof. Brenda Gamble, Ph.D. Associate Professor, Faculty of Health Sciences and Program Director, Bachelor of Health Administration & Allied Health Sciences, Ontario Tech University</p>
------------------------------	---	---

5:15 p.m. – 5:30 p.m.	Day 2 Closing Remarks and Conference Adjournment.	Filomena Servidio-Italiano, Hon B.Sc., B.Ed., M.A. President & CEO, CCRAN
-----------------------	--	---